Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

Core Insights - Iovance Biotherapeutics, Inc. will report its third quarter 2025 financial results and corporate updates on November 6, 2025 [1] - A conference call and live audio webcast will be held on the same day at 8:30 a.m. ET to discuss these results [2] Company Overview - Iovance Biotherapeutics focuses on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients [3] - The company aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [3] - Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, showcasing the company's commitment to continuous innovation in cell therapy [3]